You are here: Home » Current Affairs » Coronavirus » News
Business Standard

India declines proposal to test Sputnik-V Covid-19 vaccine in large study

India is expected to overtake the United States over the next several weeks as the country with the world's largest number of cases

Topics
Coronavirus Vaccine | Dr Reddy's Laboratories | Russia

Reuters 

Photo: Bloomberg
Photo: Bloomberg

India's drug regulator has knocked back a proposal from Dr Reddy's Laboratories Ltd to conduct a large study in the country to evaluate Russia's Sputnik-V Covid-19 vaccine and has asked it to first test the vaccine in a smaller trial.

The recommendations by an expert panel of the Central Drugs Standard Control Organisation (CDSCO) noted that safety and immunogenicity data from early-stage studies being conducted overseas is small, with no inputs available on Indian participants.

India’s move comes as a setback for Russia’s plan to roll-out the vaccine even before full trials show how well it works, while pushing back its efforts to win approval for the vaccine in the country that leads the world on average number of new infections.

India is expected to overtake the United States over the next several weeks as the country with the world’s largest number of cases.

The Russian Direct Investment Fund (RDIF), which is marketing the Sputnik V, and Dr. Reddy’s Laboratories last month announced their partnership to run clinical trials and distribute the vaccine in India.

was the first country to grant regulatory approval for a novel vaccine, and did so before large-scale trials were complete, stirring concerns among scientists and doctors about the safety and efficacy of the shot.

RDIF and Dr. Reddy’s did not immediately reply to Reuters’ requests for comment outside business hours.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 08 2020. 07:43 IST
RECOMMENDED FOR YOU